Welcome to our dedicated page for Hyperfine news (Ticker: $HYPR), a resource for investors and traders seeking the latest updates and insights on Hyperfine stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hyperfine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hyperfine's position in the market.
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced the presentation of four abstracts at the 2024 International Stroke Conference, showcasing the clinical utility and applications of portable ultra-low-field MR imaging. The Swoop® system aims to transform the diagnosis and treatment of acute ischemic stroke. The company also provided an update on the enrollment progress of the ACTION PMR study, which aims to integrate brain imaging with the Swoop® system into the stroke diagnosis and treatment workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) has obtained CE and UKCA approval for the eighth generation of Swoop® system software, which includes AI-powered features such as DWI denoising. The software has been well-received by users, improving image quality and workflow efficiencies. With international certifications, the company is poised for global expansion, aiming to bring the Swoop® system to a broader market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting. The studies analyzed how portable MR brain imaging may assist in the diagnosis and management of neurological conditions in critical care settings, showcasing the potential of portable ultra-low-field brain imaging to improve brain health. The sessions will cover topics such as longitudinal relaxivity estimation of contrast agents, generative adversarial network approach for low-field to high-field image translation, and preliminary results from a single-center retrospective study in the neurocritical care setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces participation in the Piper Sandler 35th Annual Healthcare Conference in New York. The company will present its groundbreaking FDA-cleared portable MRI brain imaging system, the Swoop® system, on November 30, 2023, at 9:30 am PT. A live webcast and archived recording will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced third quarter 2023 financial results, with revenues of $2.33 million, six commercial Swoop® systems sold, and a net loss of $10.76 million. The company also provided a business update, including FDA clearance for new AI-powered software and progress in clinical programs such as an upcoming Alzheimer's feasibility study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.37%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. announced initial findings from a multicenter study on the use of portable MR brain imaging in assessing acute brain injury in ECMO patients. The study demonstrated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use and highlighted its potential advantage in providing early visualization of ischemic stroke compared to CT scans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
Rhea-AI Summary
Hyperfine, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. promotes Dr. Edmond Knopp and Dr. Chip Truwit as vice presidents of medical affairs and scientific affairs respectively, highlighting their expertise in radiology and neuroradiology. Dr. Knopp will focus on advancing brain health in stroke care and Alzheimer's therapies, while Dr. Truwit will lead clinical innovation projects. These appointments demonstrate Hyperfine's commitment to developing ultra-low-field MR brain imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. announces FDA clearance of updated software for their Swoop® ultra-low-field brain imaging system, incorporating advanced AI algorithms for image quality enhancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
Rhea-AI Summary
Hyperfine, Inc. to present at Gilmartin Group Emerging Growth Showcase on September 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
Hyperfine, Inc.
Nasdaq:HYPR
HYPR Rankings
HYPR Stock Data
63.90M
51.21M
11.94%
26.6%
1.79%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
United States of America
GUILFORD
About HYPR
hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of